USPTO serial 79421222
PADAGIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 24, 2026
- Examiner
- POLLACK, ALISON FRIEDBERG
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PADAGIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrea M. Porterfield
Andrea M. Porterfield Polsinelli PCPO Box 140310Kansas City, MO 64114-0310United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cleaning preparations; hair lotions; shampoos; dentifrices; cosmetic creams; cosmetic preparations for face and body skin care; Non-medicated sun care preparations; cosmetic preparations for personal hygiene; cosmetic preparations for intimate care; non-medicated skin care preparations, namely, creams, lotions, gels, toners, cleaners and peels for the treatment of hemorrhoids, fissure, skin rashes, eczema, fungal infections, and itching; non-medicated skin care preparations for the treatment of hemorrhoids, fissure, skin rashes, eczema, fungal infections, and itching | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of dermatological, ophthalmic, respiratory, bacterial-based, urological, hormonal, gastrointestinal, cardiovascular, and psychiatric diseases and disorders; pharmaceutical preparations for the treatment of diabetes, migraines, and seizures; pharmaceutical preparations for use in pain management; transdermal patches for use in the treatment of nausea and vomiting; transdermal patches for the delivery of hormonal preparations; pharmaceutical preparations for inhalation for use in treatment of respiratory diseases and disorders and chronic obstructive pulmonary disease (COPD); inhalers sold filled with aerosol inhalation products, namely, antihistamines, decongestants for medical use; nasal and oral spray preparations for use as central nervous system stimulants; anti-infective preparations, namely, pharmaceutical preparations for the treatment of infectious diseases; antiviral preparations, namely, pharmaceutical preparations for the treatment of viral infections; antibiotics; antifungal preparations; anti-inflammatory preparations; cough treatment preparations; topical pharmaceutical and medical preparations for the treatment of vaginal infections; anti-fungal preparations for diaper rash, for antibiotic use, and for the treatment of alopecia; medical gels, creams and lubricants for dermatological use; disposable test strips for measuring blood glucose levels; suppositories being pharmaceutical preparations for hemorrhoids, fever and pain management; oral analgesics; topical analgesics; antacids; antihistamines; cough syrups; cough-expectorants; cough drops; decongestant preparations in the nature of decongestants in the form of tablets, capsules, nasal sprays and medicated oral care solutions and sprays; eye drops; dietary food supplements; laxatives; natural sleeping aid preparations; topical antibiotic creams and ointments; topical pharmaceutical preparations for the treatment of alopecia; pre-moistened medicated wipes; medicated eye pads for medical use; hormonal replacement therapy preparations; hormonal preparations; topical pharmaceutical preparations for hypogonadism; dermal and transdermal pharmaceutical preparations for dermatitis; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; antiparasitic preparations for veterinary purposes; pharmaceutical preparations for the treatment of acne and other skin disorders; pharmaceutical preparations for the treatment of infantile hemangioma; medicated pharmaceutical preparations for the treatment of hemorrhoids, fissure, skin rashes, eczema, fungal infections, and itching; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in oncology and haemato-oncology; pre-filled medical first aid kits and first aid prefilled injection syringes sold filled with pharmaceutical preparations for the treatment of drug overdose, cardiovascular, respiratory, seizure, gastrointestinal, infection, epilepsy, hypogonadism, itching, cold, flu, allergy, and decongestant diseases and disorders, antihistamines, as well as for pain relief and for the treatment of migraines; pharmaceutical preparations, namely, antidepressants; pro-biotic medical preparations, namely, probiotic preparations for medical use; bowel cleansing preparations being bowel evacuant preparations; medicated lozenges and oral cavity throat sprays; pharmaceutical preparations for the treatment of cold sores; pharmaceutical preparations for the treatment of sleeping disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of colds; pharmaceutical preparations for the treatment of flu; pharmaceutical preparations for the treatment of allergy; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; medicated smoking cessation preparations in the nature of gums, lozenges and oral sprays; pharmaceuticals for treating vaginal infections, namely, vaginal antifungals and vaginal suppositories for the prevention and treatment of infections; lubricants for personal use; hygienic preparations for medical use, namely medicated bath preparations for intimate hygiene; vitamin preparations; mineral food-supplements; food supplements for medical use; mineral preparations for medical use; medicinal drinks; pharmaceutical preparations for treating sunburn; pharmaceutical preparations for skin care; pharmaceutical and medicinal preparations for smoking cessation; probiotic supplements | ACTIVE | — |
| 035 | Business management services in relation to wholesale and retail of pharmaceutical, cosmetic, hygiene and beauty products for human use, food supplements and medical apparatus and instruments; demonstration of goods for promotional purposes; distribution of samples; import-export agency services; providing commercial information; sales promotion; promotional and advertising services; public relations; retail store services featuring medical pharmaceutical preparations | ACTIVE | — |
| 042 | Technical consultancy services in the field of pharmaceutical studies in relation to point-of-care products; product development consultancy services and providing product development services in the nature of technological updates in relation to self-testing products and point of care products; research and development in the fields of pharmaceuticals and medicine; research and development of new products for others; research and development of pharmaceutical preparations; design of pharmaceutical preparations; testing of pharmaceutical preparations | ACTIVE | — |
| 044 | Providing medical consultancy services in relation to self-testing and point-of-care products; medical services; veterinary services; hygienic and beauty care for human beings or animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PADAGIS US LLC
- Other trademarks owned by PADAGIS US LLC
- Other trademarks owned by PADAGIS US LLC
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PADAGIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 24, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 24, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 9, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 9, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 9, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 9, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 24, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 29, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 28, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 14, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 13, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 6, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 6, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 6, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 6, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 6, 2026 | RDX3 | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED | — |
| Jan 6, 2026 | RDX1 | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED | — |
| Jan 6, 2026 | RRDX | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED | — |
| Jan 5, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 5, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 5, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 3, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 3, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 3, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 17, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 11, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 11, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 15, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 14, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 11, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 11, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 10, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |